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Atrial fibrillation and the risk of 
myocardial infarction: a nation-
wide propensity-matched study
Hye Young Lee1,2, Pil-Sung Yang1, Tae-Hoon Kim1, Jae-Sun Uhm1, Hui-Nam Pak1, Moon-
Hyoung Lee1 & Boyoung Joung  1
In addition to being an established complicating factor for myocardial infarction (MI), recent studies 
have revealed that atrial fibrillation (AF) increased risk of MI. This study is to evaluate the risk of MI 
associated with AF in a nationwide population based cohort. We examine the association between AF 
and incident MI in 497,366 adults from the Korean National Health Insurance Service database, who 
were free of AF and MI at baseline. AF group (n = 3,295) was compared with propensity matched no-AF 
group (n = 13,159). Over 4.2 years of follow up, 137 MI events occurred. AF was associated with 3-fold 
increased risk of MI (HR, 3.1; 95% CI, 2.22–4.37) in both men (HR, 2.91; 95% CI 1.91–4.45) and women 
(HR, 3.52; 95% CI 2.01–6.17). The risk of AF-associated MI was higher in patients free of hypertension, 
diabetes, ischemic stroke, and dyslipidemia at baseline. The cumulative incidence of AF-associated MI 
was lower in patients on anticoagulant and statin therapies. Our finding suggests that AF complications 
beyond stoke should extend to total mortality to include MI.
The significance of atrial fibrillation (AF) as a major public health problem comes from its increasing prevalence 
and strong association with morbidity and mortality1,2. Patients with AF have 5 times the risk of stroke and 
double the risk of mortality compared with those without AF3,4. AF has known to complicate acute myocardial 
infarction (MI)5. In addition to being an established complicating factor for MI, recent studies have revealed that 
AF increased the risk of MI6,7. In the Atherosclerosis Risk in Communities (ARIC) study, AF was associated with 
an increased risk of non-ST segment elevation MI (NSTEMI)6. In a recent study performed by Soliman et al.7, 
AF was associated with a 70% increased risk of incident MI. However, these results are yet to be validated in a 
nationwide population based cohort and the mechanisms explaining these associations are not fully understood.
Thus, we examined the association between AF and MI by analyzing a recently developed Korean National 
Health Insurance Service–national sample cohort (NHIS-NSC) database, which includes over five hundred thou-
sand individuals. In addition, the beneficial effects of the commonly prescribed medications for AF patients on 
the occurrence of MI have not been elucidated. Herein, we also analyzed the association of medications with 
incident MI in AF patients.
Methods
Source of study data. The national health insurance service (NHIS) in Korea is a single-payer program and 
is mandatory for all residents in South Korea. This retrospective study used the NHIS-NSC 2002–2013 dataset, 
comprising a random sample of 1,025,340 subjects, which amounted to 2.2% of the entire Korean population in 
the NHIS in 2002 (46,605,433). Data were produced by the NHIS using a systematic sampling method for the 
purpose of research. Random sampling was used based on 1,476 strata8. As all individuals in South Korea are 
enrolled in the NHIS, this database represents the entire Korean population9. This is a semi-dynamic cohort data-
base; the cohort has been followed up to either the time of the participant’s disqualification of health services due 
to death or emigration or the end of the study period. The database contains eligibility and demographic infor-
mation regarding health insurance and medical aid beneficiaries, medical bill details, diagnostic codes, medical 
treatment, disease histories, prescription drug used, and personal information for inpatients and outpatient visits.
In this cohort, the subjects’ disease information was classified according to the 10th revision of the 
International Classification of Diseases (ICD-10) codes obtained from the Korean National Statistical Office 
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(Supplementary Table S1). This study was approved by the Institutional Review Board (IRB) of Yonsei University 
College of Medicine in Seoul, Korea. The IRB waived the requirement to obtain informed consent, and this study 
was conducted in accordance with the tenets of the Declaration of Helsinki.
Study population. A total of 506,805 patients, who had a health check-up between 2009 and 2013, were 
enrolled and follow-up data were reviewed until December 2013. AF cases were identified by ICD-10 codes (ICD-
10: I48)10. To ensure accuracy of diagnosis, we defined patients as AF only when it was a discharge diagnosis or 
was confirmed more than twice in the outpatient department. To further evaluate the accuracy of the definition 
of AF, a validation study was performed in 628 randomly selected patients with ICD-10 code of I48 in 2 separate 
hospitals. Their electrocardiograms (ECGs) were reviewed by two physicians. Patients were determined to have 
AF if documented by ECG. The positive predictive value was 94.1%. The clinical end point was the first occur-
rence of MI during follow up. MI cases were identified by ICD-10 codes of I21or I22, and were ascertained when 
the diagnosis was confirmed by hospitalization or death from MI. To evaluate the accuracy of our definition of 
MI, we conducted a validation study with medical records of two independent tertiary hospitals from 2006–2013. 
A total of 4,688 patients were found to have ICD codes of I21 or I22. Data of clinical history, cardiac biomarkers, 
ECGs and the results of coronary angiography were reviewed by two cardiologists. The positive predictive value 
was 86.5%.
Medical records of all patients were reviewed from 2002 till 2013 in order to clarify the newly diagnosed AF 
and MI during the study period. The laboratory and survey questionnaire data of general and life-transition 
health examinations for all cohort members were merged.
Of the 8,296 patients with AF, patients who had AF or MI before 2009 (n = 4,976) and who suffered an MI 
before AF (n = 25) were excluded. Finally 3,295 patients were enrolled in the AF group. Among those without 
AF (n = 498,509), 494,071 patients were enrolled in the no-AF group after excluding the patients who suffered 
an MI before 2009 (n = 4,438). Given the differences in the baseline characteristics and the risk of cardiovascular 
diseases between the AF and control groups, we used 1:4 propensity score matching and calculated the propensity 
score, with predicted probability of AF occurrence conditional on baseline covariates, by multivariable logistic 
regression (Table 1)11. We attempted to match each patient in the AF cohort with a patient in the control cohort 
with a similar propensity score, based on nearest-neighbor matching without replacement, using a caliper width 
equal to 0.05 of the standard deviation of the logit of the propensity score. Pre- and post-match absolute stand-
ardized differences were presented as Love Plots12.
The following variables were entered: age, sex, and a history of congestive heart failure, hypertension, diabetes 
mellitus, chronic kidney disease (CKD) or end-stage renal disease (ESRD), dyslipidemia, ischemic stroke, periph-
eral artery occlusive disease (PAOD), chronic obstructive pulmonary disease (COPD), history of malignancy, 
anemia, smoking history, blood pressure, body mass index, waist circumference, body surface area, cholesterol 
level, serum creatinine, and estimated –glomerular filtration rate (eGFR). Covariates included in propensity 
matching were the data from baseline examination at the time of health check-up, and the definitions of comor-
bidities were based on ICD codes. The matching procedure was performed using R packages (R Foundation 
for Statistical Computing, Vienna, Austria), including Matchit, RItools, and CEM13. Finally, a total of 3,295 AF 
patients and 13,159 no-AF patients were evaluated in this study (Fig. 1).
Statistical analysis. Data were presented as mean ± SD for normally distributed continuous variables and 
as proportions for categorical variables. Age-adjusted incidence rate of MI per 1000 person-years in patients with 
and without AF was calculated in the propensity matched population and in the sex subgroup. Person-time for 
the incidence rate in the AF group was calculated from AF diagnosis to the occurrence of MI or censoring. In the 
no-AF group, person-time was calculated from baseline to MI occurrence or censoring. Cumulative incidence 
of MI was plotted using a Kaplan-Meier method, with statistical significance examined using log-rank test by AF 
status. The risk of MI was assessed using Cox regression analysis. Statistical analysis was performed using SPSS 
Figure 1. Study population. NHIS HCK, National Health Insurance Service-health check-up; AF, atrial 
fibrillation; MI, myocardial infarction.
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21.0 statistical software (SPSS Inc., Chicago, IL, USA). All p-values were two tailed, and values less than 0.05 were 
considered statistically significant.
Results
Baseline characteristics. The mean age of matched patients was 63 years (range, 19–98 years) and 58% of 
the patients were male. Table 1 shows the baseline characteristics of the study population stratified by AF status. 
In the full pre-match cohort, patients with AF were older, had a higher body mass index, a higher prevalence 
of heart failure (HF), hypertension, diabetes, CKD or ESRD, dyslipidemia, ischemic stroke, PAOD, and COPD 
(all P < 0.001). Mean CHA2DS2-VASc score was 2.6 ± 1.9 in the AF group and 1.2 ± 1.3 in the no-AF group 
(P < 0.001). Covariates with significant imbalances in the pre-matched cohort which were well balanced after 
propensity matching are displayed in Table 1. Absolute standardized differences in all measured covariates were 
less than 5%, suggesting substantial covariate balance across the groups (Supplementary Fig. S1).
Aspirin, anticoagulants, statin, digoxin, beta blocking agent (BB), and calcium channel blocker (CCB) were 
more frequently prescribed in the AF group than in the no-AF group; aspirin (50.3% vs. 27.5%, P < 0.001), anti-
coagulant (20.9% vs. 0.3%, P < 0.001), statin (38.2% vs. 28.5%, P < 0.001), digoxin (13.4% vs. 0.9%, P < 0.001), BB 
(43.1% vs.16.1%, P < 0.001), and CCB (11.4% vs. 2.5%, P < 0.001).
AF and the risk of MI. Over 4.2 years of follow up, 137 incident MI events occurred. Figure 2 shows the 
unadjusted cumulative incidence of MI stratified by baseline AF status in the entire cohort (Fig. 2a) and the 
matched cohort (Fig. 2b). Patients with AF had a higher incidence of MI than those without AF in both the entire 
cohort and the matched cohort (log rank p < 0.001 for both cohorts).
The age-adjusted incidence rate of MI among participants was higher in those with AF than in those without 
AF (4.42 vs 1.42 per 1000 person-years), with an incidence rate ratio (IRR) of 3.12 [95% CI, 2.23–4.36]. In a sex 
stratified analysis, the higher age-adjusted MI IRRs by AF status was observed in women (IRR, 3.65; 95% CI, 



















Age, years 47.4 ± 14.2 62.8 ± 12.9 1.194  < 0.001 62.9 ± 12.9 62.8 ± 12.9 −0.006 0.877
Female, % 50.1 42 −0.173  < 0.001 42.1 42.0 −0.003 0.874
Systolic BP, mmHg 122.1 ± 15.3 128.3 ± 16.9 0.366  < 0.001 128.5 ± 16.1 128.3 ± 16.8 −0.012 0.577
Diastolic BP, mmHg 76.0 ± 10.2 78.6 ± 10.6 0.245  < 0.001 78.8 ± 10.2 78.6 ± 10.7 −0.012 0.586
Body mass index, kg/m2 23.7 ± 3.3 24.3 ± 3.4 0.190  < 0.001 24.3 ± 3.2 24.3 ± 3.4 0.003 0.884
Waist circumference, cm 79.9 ± 9.3 83.9 ± 9.1 0.449  < 0.001 84.0 ± 8.6 84.0 ± 9.1 0.003 0.629
Heart failure, % 1.9 11.5 0.299  < 0.001 10.1 11.5 0.038 0.023
Hypertension, % 20.7 57 0.732  < 0.001 56.5 57 0.009 0.609
Diabetes, % 12.3 32.1 0.426  < 0.001 31.3 32.1 0.017 0.345
CKD or ESRD, % 5.6 17.3 0.309  < 0.001 16.6 17.3 0.015 0.348
Dyslipidemia, % 18.6 38.1 0.400  < 0.001 38.2 38.1 −0.003 0.952
Ischemic stroke, % 2.4 9.3 0.239  < 0.001 9.1 9.3 0.005 0.737
PAOD, % 6.9 19.4 0.315  < 0.001 19.2 19.4 0.005 0.768
COPD, % 6.0 17.3 0.298  < 0.001 16.6 17.3 0.015 0.355
History of malignancy, % 6.6 14.1 0.218  < 0.001 13.7 14.1 0.011 0.553
Anemia, % 11.8 16.7 0.245  < 0.001 16.3 16.2 −0.004 0.873
Smoking, % 37.6 39.4 0.021 0.042 38.4 39.4 0.004 0.304
Total cholesterol, mg/dl 195.1 ± 37.2 192.9 ± 39.4 −0.054 0.001 192.9 ± 37.8 192.9 ± 39.3 0.002 0.876
Triglyceride, mg/dl 131.9 ± 94.1 139.2 ± 88 0.088  < 0.001 139.6 ± 86.7 139.2 ± 88.2 −0.004 0.799
HDL-cholesterol, mg/dl 56.5 ± 27.9 55.1 ± 36.5 −0.028 0.025 54.8 ± 35.3 55.1 ± 36.5 0.006 0.721
LDL-cholesterol, mg/dl 113.8 ± 37.6 112.4 ± 38.7 −0.031 0.038 112.8 ± 38.8 112.4 ± 38.7 −0.007 0.553
Serum creatinine, mg/dl 1.0 ± 1.1 1.1 ± 1.2 0.079  < 0.001 1.09 ± 1.2 1.10 ± 1.2 0.007 0.693
eGFR-CKD-EPI 89.5 ± 21.1 76.7 ± 21.1 −0.601  < 0.001 77.4 ± 20.5 77.1 ± 20.9 −0.010 0.507
CHADS2 0.5 ± 0.9 1.4 ± 1.4 0.995  < 0.001 1.4 ± 1.4 1.4 ± 1.4 0.029 0.131
CHADS-VASc 1.2 ± 1.3 2.6 ± 1.9 1.073  < 0.001 2.5 ± 2.0 2.6 ± 2.0 0.026 0.225
Table 1. Baseline characteristics by AF status before and after propensity score matching Data are presented 
as mean ± SD for continuous variables and as proportions for categorical variables. AF, atrial fibrillation; CKD, 
chronic kidney disease; ESRD, end–stage renal disease; PAOD, peripheral artery obstructive disease; COPD, 
chronic obstructive pulmonary disease; HDL, high-density lipoprotein; LDL, low-density lipoprotein; eGFR-
CKD-EPI, estimated glomerular filtration rate-chronic kidney disease-epidemiology collaboration; CHADS2, 
congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, stroke; VASc, Vascular disease, age 
65–75 years, sex category.
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In a Cox proportional hazards model of the matched cohort, AF [Hazard ratio (HR), 3.12; 95% CI, 2.23–
4.37, p < 0.001] was an independent risk factor for MI. Other risk factors were hypertension (HR, 1.87; 95% 
CI, 1.30–2.69, p < 0.001), diabetes (HR, 1.79; 95% CI, 1.28–2.51, p < 0.001), HF (HR, 2.04; 95% CI, 1.32–3.14, 
p = 0.003), CKD or ESRD (HR, 2.70; 95% CI, 1.90–3.85, p < 0.001) and dyslipidemia (HR, 1.45; 95% CI, 1.04–
2.03, p = 0.031) (Table 2).
Figure 2. Unadjusted cumulative incidence of myocardial infarction by baseline atrial fibrillation status in the 
entire cohort (a) and in the propensity scored matched cohort (b). Cumulative incidence was calculated using 
Kaplan-Meier estimates and compared using the log-rank test.
Figure 3. Age-adjusted incidence rate and incidence rate ratios of myocardial infarction by atrial fibrillation 
status. Incidence rate per 1,000 person-years. *Age adjusted incidence rate and incidence rate ratios were based 
on the average of the cohort.
HR 95% CI p-value
Age, per 1 year 1.05 1.03–1.07  < 0.001
Atrial fibrillation 3.12 2.23–4.37  < 0.001
Heart failure 2.04 1.32–3.14 0.003
Hypertension 1.87 1.30–2.69  < 0.001
Diabetes 1.79 1.28–2.51  < 0.001
CKD or ESRD 2.70 1.90–3.85  < 0.001
Dyslipidemia 1.45 1.04–2.03 0.031
Ischemic stroke 1.71 1.05–2.77 0.030
COPD 2.18 1.51–3.15  < 0.001
Anemia 1.54 1.02–2.30 0.038
Waist circumference 1.03 1.01–1.05 0.011
Table 2. The independent clinical predictors of myocardial infarction in propensity score matched cohort. 
HR, hazard ratio; CI, confidence interval; CKD, chronic kidney disease; ESRD, end stage renal disease; COPD, 
chronic obstructive pulmonary disease
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Association of AF with MI in subgroups. The associations of AF with MI among various subgroups of 
patients are displayed in Fig. 4. The risk of hospitalization or death due to MI was significantly higher in the AF 
group than in the no-AF group, regardless of age (p for interaction = 0.1), sex (p for interaction = 0.6), comor-
bidities with HF (p for interaction = 0.11), and CKD or ESRD (p for interaction = 0.56) at baseline. On the other 
hand, we found that the risk of AF associated incident MI was higher in patients free of hypertension [HR, 
7.87 (95% CI, 4.13–15.0) vs. 2.06 (95% CI, 1.35–3.14), p for interaction = 0.001], diabetes [HR, 4.89 (95% CI, 
3.13–7.67) vs. 1.66 (95% CI, 0.72–3.84), p for interaction = 0.003], ischemic stroke [HR, 3.50 (95% CI, 2.44–5.03) 
vs. 1.407 (95% CI, 0.51–3.91), p for interaction = 0.002], and dyslipidemia [HR, 4.49 (95% CI, 2.84–7.09) vs. 1.98 
(95% CI, 1.18–3.35), p for interaction = 0.021] at baseline.
Risk of MI in association with medications in AF patients. Medications analyzed in this study were 
aspirin, anticoagulants, statin, digoxin, BB and CCB. Anticoagulants included in the analysis were warfarin, direct 
thrombin inhibitor and factor Xa inhibitors. Pharmacological treatment was ascertained when there were at least 
90 days or more prescriptions were prescribed after the incident diagnosis of AF.
Figure 5 shows the effect of each medication on the occurrence of MI in AF patients. Anticoagulants were 
prescribed in 688 of the 3,295 AF patients without gender difference in prescription rate (men, 21.1% vs. women, 
20.6%, p = 0.76). AF associated incident MI occurred less in patients on anticoagulant (0.6% vs. 2.1%, p = 0.004). 
Statins were prescribed in 1,259 of the 3,295 AF patients and prescription rate was higher in women than in men 
(men, 34.1% vs. women, 43.9%, p < 0.001). AF associated incident MI was less in patients on statin therapy (1.3% 
vs. 2.2%, p = 0.05). Cumulative incidence of MI was lower in patients who were taking an anticoagulant (Fig. 5b, 
p = 0.004) and statin (Fig. 5c, p = 0.039). Aspirin users showed a similar trend, which did not reach statistical sig-
nificance (Fig. 5a, p = 0.058). The most commonly prescribed rate control agent was BB, followed by digoxin and 
CCB. AF-associated MI events did not differ between patients who were taking digoxin (Fig. 5d), BB (Fig. 5e), 
and CCB (Fig. 5f) and those who were not taking these medications. Overall death, regardless of the mode of 
death, occurred more often in patients with MI than in those without MI during the follow up period (35.8% vs 
4.6%, p < 0.001).
Discussion
In this study from NHIS, our principal findings are as follows: (1) AF was significantly associated with increased 
risk of incident MI. (2) Association between AF and the risk of MI did not differ by sex. (3) The risk of AF associ-
ated incident MI was higher in patients free of hypertension, diabetes, ischemic stroke, and dyslipidemia. (4) The 
incidence of AF associated incident MI was lower in patients on anticoagulant and statin therapies.
In this study, AF was associated with 3-fold increased risk of MI, even after the risk factors and potential 
confounders for MI were included in the matching. These findings were in accordance with the recently reported 
several studies which showed AF as an independent risk factor for MI6,7,14,15.
Figure 4. Effects of atrial fibrillation on the risk of myocardial infarction in different groups of patients. CI, 
confidence interval. Hazard ratios were calculated based on Cox regression after propensity matching. The P for 
interaction was calculated using the interaction term for AF and each subgroup based on Cox regression.
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Contrary to recent studies which showed gender difference in the association between AF and MI6,7,15, it were 
not observed in this study. Previously, it was reported that women were less likely to receive warfarin than men16,17 
and this may be the possible explanation for gender difference of MI14. However, in our study, use of anticoagulant 
did not differ between sex and this, in part, may contribute to the similar risk of MI between men and women.
Notably, we confirmed that the risk of MI was significantly higher in patients with AF free of overt cardiovas-
cular disease than in subjects without AF. Previous study from Olmsted County revealed that lone AF had a com-
parable risk of embolic events and mortality to the general population18,19. In contrast, recent studies showed that 
patients with AF without cardiovascular co-morbidities had an increased risk of cardiovascular events and mor-
tality15,20. These interactions suggest that shared underlying risk factors are not the only mechanisms explaining 
the association between AF and MI. There are plausible explanations for why AF patients with less co-morbidity 
were predisposed to MI. In patients with established risk factors for MI, AF may contribute less to the occurrence 
to MI, compared with those who were previously healthy. In our study, anticoagulants showed beneficial effect 
against AF associated incident MI. Accordingly, embolic events to coronary arteries are another possible explana-
tion. Statin use, and also, is higher in patients with cardiovascular diseases, which may decrease the incident MI. 
Further study is needed in this regard.
In this analysis stratified by medications after AF diagnosis, the risk of incident MI was less in anticoagulant 
users. Previously, it was reported that warfarin might have a protective effect against MI21. Prevention of throm-
bus formation with anticoagulation, in part, might be an explanation. In our study, the anticoagulants analyzed 
were direct thrombin inhibitor, factor Xa inhibitors, as well as warfarin, and whether the new oral anticoagulants 
could have a role in preventing MI in the setting of AF needs to be further investigated.
Clinical trials have already demonstrated a clear beneficial effect of statin for prevention of ischemic heart 
disease22,23. In accordance with these studies, this study revealed that the risk of AF associated incident MI was 
less in statin users than in non-users. In a study, association between AF and inflammation has been reported24. 
The role of inflammation in MI has already been established25. Anti-inflammatory and anti-thrombotic activities 
of statin may reduce the risk of AF associated incident MI.
Type 2 MI can occur due to poorly controlled ventricular response in AF patients26. The rate control strategy 
in AF patients is expected to reduce the occurrence of type 2 MI, by reducing the oxygen demand and by increas-
ing the diastolic filling time of coronary arteries. However, the result of this study was not in accordance with 
this common belief, suggesting that type 2 MI is less likely to be the main mechanism by which AF leads to MI.
Considering MI as a known risk factor for AF27, this result suggests a bidirectional relationship between AF 
and MI. However, the pathophysiology of AF associated incident MI is complex and incompletely understood. 
Further research to determine the underlying mechanism with the association of AF and MI is warranted. The 
Figure 5. Risk of incident myocardial infarction associated with medication in patients with atrial fibrillation. 
The cumulative incidences of myocardial infarction were calculated using Kaplan-Meier estimates and 
compared using the log-rank test.
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prevalence of AF doubles with each additional decade of life28. With an increasing older population, the occur-
rence of AF itself and AF-associated morbidity and mortality is expected to increase as well. From a preventive 
perspective, the notion should suggest that AF potentiates the risk of MI.
Limitations
There are several limitations to this study. Although we ascertained AF cases with ECGs as well as ICD codes, it 
is possible that paroxysmal or asymptomatic AF cases were not detected. Also, we could not analyze paroxysmal, 
persistent and permanent AF separately. Second, because MI cases were identified by ICD-10 code, data for car-
diac markers, ECGs, and coronary angiography were not available, which could have provided further information 
about the type of MI26. We could not analyze the association of AF with different types of MI. Third, even though 
the NHIS recommends biennial health check-up to all health insurance subscribers, it is not compulsory and there 
is a possibility that healthier and more educated subjects could have participated in this study. Fourth, potentially 
uncontrolled covariates may exist because comorbidities included in propensity matching are the data from baseline 
examination. They may be absent at baseline, but may have developed during the follow-up. Fifth, similar to other 
studies, considerable confounders may remain although propensity-score matching was well balanced. Despite the 
limitations, this study is the nation-wide population based observational studies providing the further evidence for a 
link between AF and MI, and the effects of medications on the occurrence of AF related incident MI.
Conclusions
AF is associated with an increased risk of MI in the nationwide cohort study of Korean population. The associ-
ation between AF and MI did not differ by sex and higher in patients free of cardiovascular diseases at baseline. 
Anticoagulants and statin showed beneficial effects against MI in AF patients. Our finding suggests that AF com-
plications beyond stroke should extend to total mortality to include MI.
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